Pharmacological treatment of obesity

Pharmacological and Surgical Treatment of Obesity: Summary

The age-adjusted prevalence of obesity in the United States was 30.5 percent in 1999-2000. Although obtaining a precise estimate of the change in the prevalence of obesity over time is difficult because of changing definitions, nearly all clinical authorities agree that obesity is reaching epidemic proportions. In response, pharmacological and surgical treatments for weight loss have become bot...

Pharmacological Treatment of Obesity in Patients with Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is a common disorder affecting women of reproductive age and it is associated with increased cardiovascular risk. Obesity plays an important role in the pathogenesis of PCOS, and the majority of patients with PCOS are obese. Over the last 20 years, the prevalence of obesity has dramatically increased, with probable associated increase in PCOS. Weight reduction p...

Recent advances in the pathophysiology and pharmacological treatment of obesity.

WHAT IS KNOWN AND OBJECTIVE The increasing prevalence of obesity and associated morbidity present unmet medical needs for safe and effective new drug therapies. Our aim is to review the diverse targets and compounds that are in clinical development. METHODS Literature searches were conducted using the PUBMED database for studies published in English from January 1985 to December 2011 using co...

Pharmacological treatment of obesity: a public health perspective.

Emerging pharmacological approaches to the treatment of obesity.

The obesity epidemic has been recognized by the World Health Organization (WHO) as one of the top 10 global health problems. Worldwide, more than one billion adults are overweight and over 300 million are obese. The majority of developed countries, including the United States, Canada and England are experiencing dramatic increases in obesity. Obesity is a condition associated with the accumulat...